Seres Therapeutics, Inc. Income Statement

Income Statement Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 21.77M32.10M28.27M34.51M33.22M144.93M7.13M126.33M
Gross Profit 21.77M32.10M28.27M34.51M33.22M144.93M7.13M126.33M
Operating items
Research & Development 38.09M81.99M89.45M95.95M80.14M90.57M141.89M109.65M117.60M64.60M
Selling, General & Administrative 16.76M32.62M34.04M32.60M24.75M30.77M69.26M70.26M77.50M53.18M
Restructuring Costs 1.49M
Other Operating Expenses 1.73M3.53M
Operating Expenses 54.86M114.61M123.50M128.55M106.38M121.34M209.42M179.91M195.10M121.31M
Operating Income -54.86M-92.84M-91.39M-100.28M-71.88M-88.13M-64.49M-179.91M-195.10M-121.31M
EBIT -54.86M-92.84M-91.39M-100.28M-71.88M-88.13M-64.49M-179.91M-195.10M-121.31M
Non-operating items
Interest & Investment Income 0.64M1.26M1.59M1.17M1.03M0.95M2.87M3.06M7.30M3.97M
Other Non Operating Income -0.01M0.42M0.17M1.07M0.98M-1.04M-0.70M0.13M-14.11M
Non Operating Income 0.08M1.26M2.02M1.34M1.60M-1.00M-1.08M-3.67M4.97M-14.11M
Net income details
EBT -54.22M-91.58M-89.81M-99.11M-71.34M-90.11M-64.53M-182.88M-190.26M-117.35M
Profit After Tax -54.78M-91.58M-89.38M-98.94M-70.28M-89.13M-65.58M-250.16M-190.13M-125.77M
Income from Continuing Operations -54.22M-91.58M-89.81M-99.11M-71.34M-90.11M-64.53M-182.88M-190.26M-117.35M
Consolidated Net Income -54.22M-91.58M-89.81M-99.11M-71.34M-90.11M-64.53M-66.58M76.41M125.91M
Income towards Parent Company -54.22M-91.58M-89.81M-99.11M-71.34M-90.11M-64.53M-66.58M76.41M125.91M
Net Income towards Common Stockholders -54.78M-91.58M-89.38M-98.94M-70.28M-89.13M-65.58M-250.16M76.41M125.91M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 1.95M2.02M2.03M2.04M3.50M4.56M4.59M6.23M6.46M8.54M
Shares Outstanding (Diluted Average) 79.79M91.70M108.08M128.00M155.40M
EBITDA -54.75M-91.76M-89.38M-98.80M-70.28M-89.17M-65.59M-250.11M-113.71M0.14M